I-MAB Biopharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
I-MAB Biopharma - overview
Established
2016
Location
Rockville, MD, US
Primary Industry
Pharmaceuticals
About
Founded in 2014 and headquartered in Rockville, US, I-MAB Biopharma specializes in the R&D of precision immuno-oncology agents for the treatment of cancer. In January 2020, it was listed on NASDAQ under the ticker IMAB. I-MAB Biopharma engages in the R&D of novel therapeutics across oncology, autoimmune disorders, and metabolic diseases. Its portfolio includes immunoglobulin Fc-fusion polypeptides for diabetes treatment, GLP-1 analogues for blood glucose reduction, and multiple immuno-oncology drug candidates aimed at enhancing cancer treatment outcomes.
The company integrates in-house discovery with external partnerships to advance first-in-class and best-in-class biologics. The company generates revenue from collaborative licensing agreements, R&D partnerships, milestone payments, and future sales of proprietary biologic drug candidates.
Current Investors
I-Bridge Capital, CBC Group, Tasly Pharmaceutical Co., Ltd.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.i-mabbiopharma.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
I-MAB Biopharma - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 11,556,000 | 53,781,000 | 30,000,000 | - | - | - |
| % Revenue Growth (YoY) | - | 365.4% | (44.2%) | - | - | - |
| EBITDA (USD) | (279,321,000) | (431,898,000) | (1,449,334,000) | - | - | - |
| Operating Income (USD) | (280,955,000) | (438,638,000) | (1,464,968,000) | - | - | - |
| Operating Margin | (2431.2%) | (815.6%) | (4883.2%) | - | - | - |
| % EBITDA Margin | (2417.1%) | (803.1%) | (4831.1%) | - | - | - |
| NET Income (USD) | (298,240,000) | (402,833,000) | (1,451,950,000) | - | - | - |
| % Net Margin | (2580.8%) | (749.0%) | (4839.8%) | - | - | - |
I-MAB Biopharma - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Chief Executive Officer | BM | ||||||
| Member of the Board | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.